Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

Abstract

International audienc

Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma

“…In the BVD regimen, severe adverse events were reported for 65 % of patients mostly due to infections (23.2 %). Few severe hematological side effects were reported (20.5 % neutropenia, 9.5 % thrombocytopenia, 5.5 % anemia) (Rodon et al 2015). In the study conducted by Offidani et al (2013) with the BVD regimen, common severe adverse events were thrombocytopenia (30.5 %), neutropenia (18.5 %), infections (12 %) and neuropathy (8 %).…”

“…OS was estimated at 13.3 months. Rodon et al (2015) conducted a phase II study of BVD in elderly patients (>65 years) with one previous line of therapy. ORR was 67 % (CR 10.9 %, VGPR 16.5 %, PR 39.7 %), and median OS was estimated at 23 months.…”

Emerging biological insights and novel treatment strategies in multiple myeloma

“…The combination of bendamustine with bortezomib and dexamethasone shows a remarkable antimyeloma activity with manageable toxicity in previously treated MM patients [274,275].…”

The multicenter experience with bendamustine in the treatment of relapsed and refractory multiple myeloma

“…ОЧО соста-вила 67,1 %, из них у 10,9 % пациентов достигнут ПО и у 12,3 % -ОХЧО, у 34,2 % -ЧО. Еще у 13,6 % пациентов достигнута стабилизация заболевания (СЗ), а оставшиеся 10,3 % пациентов были рефрактерными к терапии [12].…”